Association testing among control patients, patients with pSS with anti Sjögren's Syndrome A+ (SSA+), pSS patients with anti SSA and anti SSB+, and patients with pSS with systemic manifestations using logistic regression adjusting for top 2 PCs of AIMs
| SNP . | Number of minor alleles (%) . | SSA+ pSS vs controls . | SSA+ and SSB+ pSS vs controls . | Systemic pSS vs controls . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Controls (N = 451) . | Anti SSA+ (N = 335) . | Anti SSA+ and SSB+ (N = 176) . | Systemic manifestations (N = 307) . | OR . | P . | OR . | P . | OR . | P . | |
| rs13192841 | 243 (28) | 183 (27) | 94 (27) | 166 (27) | 0.92 | .5 | 0.89 | .42 | 0.93 | .57 |
| rs2230926 | 55 (6) | 49 (7) | 26 (8) | 43 (7) | 1.54 | .051 | 1.66 | .06 | 1.39 | .15 |
| rs6922466 | 220 (25) | 165 (25) | 82 (24) | 166 (27) | 0.99 | .95 | 0.91 | .54 | 1.11 | .39 |
| SNP . | Number of minor alleles (%) . | SSA+ pSS vs controls . | SSA+ and SSB+ pSS vs controls . | Systemic pSS vs controls . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Controls (N = 451) . | Anti SSA+ (N = 335) . | Anti SSA+ and SSB+ (N = 176) . | Systemic manifestations (N = 307) . | OR . | P . | OR . | P . | OR . | P . | |
| rs13192841 | 243 (28) | 183 (27) | 94 (27) | 166 (27) | 0.92 | .5 | 0.89 | .42 | 0.93 | .57 |
| rs2230926 | 55 (6) | 49 (7) | 26 (8) | 43 (7) | 1.54 | .051 | 1.66 | .06 | 1.39 | .15 |
| rs6922466 | 220 (25) | 165 (25) | 82 (24) | 166 (27) | 0.99 | .95 | 0.91 | .54 | 1.11 | .39 |